HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Anti-TNF Alpha Therapy Apoptosis Asthma Autocrine Signaling Autoimmune Disorder B Cells benign Biofluid Biology of neoplasia Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Blood Brain Breast Cancer Breast milk Cancer Genomics Cardiovascular Disease CD3 CDKN2A mutation Cells Cerebrospinal Fluid Chemokines Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs cMET Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA Cytokines Cytotoxic T Cells Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT Encephalophy epidemiology epigenomics Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap FGFR Fibrous Tumors Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HLA-E Homing HPV HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immunohistochemistry IHC Immunotherapy Inflammation Integrins Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lung cancer Lupus Lymph Node Metastasis Lymphocytes Lymphoma machine learning malignant Mechanism of Action Melanoma Mesothelioma MET Method Comparison Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway mTOR signaling multi-omics Multiple Myeloma Muscle Mutations MYC NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Neurologic non-Hodgkin Lymphoma Novel Therapeutic Targets NTRK1 Oesophageal Adenocarcinoma Oncology Oncology-Biomarker Oral Cancer Osteoarthritis Osteoclast Ovarian cancer Pancreas Paralysis Parkinson's Disease Pathogenesis Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PFAS PIK3CA mutation placenta Placenta Plasma Platform Comparison predictive biology Predictive Biomarkers Predictive Modeling Programmed cell death protein 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radioimmunotherapy Rearrangements Renal Cell Carcinoma Renal Disease Reproductive Response rate RET Reveal Rheumatoid Arthritis Risk Score ROS1 safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus VEGFR Wound healing Xenograft Tissue

2021

High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL)

Pritchett, J. C., et al., High-dimensional and single-cell transcriptome analysis of tumor microenvironment in angioimmunoblastic T cell lymphoma AITL), Leukemia 2021. https://doi.org/10.1038/s41375-021-01321-2

View External Link

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure

Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure. Poster presentation presented at: 16th International Conference on Malignant Lymphoma (ICML) Lugano. June 18-22, 2021

Download pdf 3.4MB

2020

Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.

View External Link

Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study

Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.

View External Link

Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma

Tiemann, A., et al. Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma. Poster and Abstract 263 presentedDeutsche Gesellschaft Fur Hamatologie Und Medizinische Onkologie.  at Virtual Annual Meeting 2020 OCT 9 - 11. 

View External Link

Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial

Menter, T., et al. Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial.  British Journal of Haematology; 2020 Jun. doi: 10.1111/bjh.16876

Download pdf 858KB

Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up

Zhou H., et al. Prognostic Factors, Therapeutic Approaches, and Distinct Immunobiologic Features in Patients with Primary Mediastinal Large B-cell Lymphoma on Long-term Follow-up. Blood Cancer Journal (2020)10:49

Download pdf 1.0MB

2019

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination

Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland.  Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629

View External Link

Page last updated September 16, 2021